HSD17B1 and breast cancer: Initially, it should be clarified that the use of Epirubicin hydrochloride as a reference compound in this study serves as a strategic standard to assess the therapeutic potential of novel retinoic acid derivatives compared to an established chemotherapeutic agent in the treatment of BC, despite the different mechanism of action of 17beta‐HSD1 inhibitors.